Have any questions? 706-721-6582 or cts@augusta.edu
- D081RC00001 A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)
Clinical Trial
D081RC00001 A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination with Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O)
The purpose of this study is to find out if new treatment with durvalumab with or without olaparib when added to the standard of care chemotherapy and bevacizumab, could help defer or prevent relapse of your disease and whether these treatments cause any side effects.
Eligibility Criteria
- To be eligible for this study, the patient must provide sufficient formallin fixed, parraffin embedded (FFPE) tumour sample suitable for the Myriad myChoice HRD Plus test. Patients must be at least 18 years of age or older; Female patients with newly diagnosed, histologically confirmed, advanced high grade epithelial ovarian cancer including high grade serous, high grade endometriod, clear cell ovarian cancer or carcinosarcoma.
RESEARCH. INNOVATION. DISCOVERY.